

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

PROPOSED ELECTION OF NON-EXECUTIVE DIRECTOR

麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the twentieth meeting of the eleventh session of the board of directors (the “**Board**”) of the Company elected Mr. Lin Nanqi (林楠棋先生) (“**Mr. Lin**”) as the non-executive director of the eleventh session of the Board. Mr. Lin will be entitled to an annual director fee of RMB96,000 during his term. The remuneration of Mr. Lin has been reviewed by the Remuneration and Assessment Committee and determined by the Board with reference to his duties and responsibilities within the Company, the Company’s remuneration policy and the market salary level for the same position. The appointment of Mr. Lin shall be subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of ordinary resolution at the 2024 third extraordinary general meeting of the Company (the “**EGM**”). The term of Mr. Lin as a non-executive Director will commence on the date when the Shareholders approve his election at the EGM and end upon the expiry of the term of the eleventh session of the Board. The Company will enter into a service agreement with Mr. Lin upon the approval of his election at the EGM.

The biography of Mr. Lin is as follows:

Mr. Lin Nanqi (林楠棋), aged 42, holds a bachelor's degree in engineering from Tianjin University of Commerce (天津商業大學) (formerly Tianjin University of Commerce (天津商學院)). Before joining the Company, Mr. Lin served as the workshop manager, production director, and deputy general manager of Livzon Group Xinbeijiang Pharmaceutical Manufacturing Inc.* (麗珠集團新北江製藥股份有限公司) from October 2008 to December 2012, chairman and general manager of Jiaozuo Joincare Pharmaceutical Industry Co., Ltd.* (焦作健康元生物製品有限公司) from December 2012 to June 2024, director and general manager of Shenzhen Haibin Pharmaceutical Co., Ltd.* (深圳市海濱製藥有限公司) from May 2018 to April 2024, the executive director of Shenzhen Taitai Pharmaceutical Co., Ltd.* (深圳太太藥業有限公司) from November 2018 to June 2024 and the executive vice president of Joincare Pharmaceutical Group Industry Co., Ltd.* (健康元藥業集團股份有限公司) (Shanghai Stock Exchange stock code: 600380) (“**Joincare**”) from April 2024 to August 2024. Since December 2019, he has been a director of Joincare, and since August 2024, he has also been the president of Joincare.

As at the date of this announcement, save as disclosed above, Mr. Lin (i) does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders (as defined under the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Hong Kong Listing Rules**”)) of the Company; (ii) does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) does not hold any other position with the Company and other members of the Group; and (iv) has not hold any directorship in any listed companies in Hong Kong or overseas in the last three years preceding the date of this announcement.

Save as disclosed above, there is no other information that need to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules nor are there other matters related to the election of Mr. Lin that need to be brought to the attention of the Shareholders.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China
23 October 2024

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman) and Mr. Qiu Qingfeng; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*